Today President Biden released his proposed Fiscal Year (FY) 2024 federal budget with an emphasis on increased funding for medical research and expanded access to health insurance.
March 9, 2023
February 8, 2023
“ASCO applauds President Biden’s focus on ‘ending cancer as we know it’ during the State of the Union address. We continue to urge the president to keep cancer care and research as top national priorities and are pleased with his plans to advance efforts to strengthen the Cancer Moonshot, improve cancer clinical trials, and foster breakthroughs through the Advanced Research Projects Agency for Health (ARPA-H).”
October 26, 2022
The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) today released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The statement was published in the AACR’s journal Clinical Cancer Research and ASCO’s Journal of Clinical Oncology.
August 10, 2022
The American Society of Clinical Oncology (ASCO) applauds President Biden for his decision to appoint ASCO-Past President Monica M. Bertagnolli, MD, FACS, FASCO, as the new Director of the National Cancer Institute (NCI). An accomplished cancer surgeon and researcher with deep expertise in community-based cancer research, Dr. Bertagnolli has the knowledge, passion, and skillset to successfully lead the nation’s top federal cancer research agency and the wider U.S. cancer research enterprise. We enthusiastically endorse her selection, recognizing Dr. Bertagnolli’s distinguished leadership and experience in advancing evidence-based cancer care and research.
June 23, 2022
“The Association for Clinical Oncology (ASCO) applauds the Food and Drug Administration’s (FDA) decision to remove Juul products from the market in the United States (U.S.). This is an important step in preventing another generation from becoming addicted to nicotine—regardless of how it is delivered.”
January 14, 2022
In many areas of the United States, the healthcare system is facing critical workforce shortages. The American Society of Clinical Oncology (ASCO) encourages public health officials and healthcare facilities to follow Centers for Disease Control and Prevention (CDC) guidelines for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-CoV-2. These guidelines allow for different levels of restrictions on staffing based on the level of shortages being experienced. However, in making these decisions, ASCO strongly encourages institutions and public health agencies to recognize the greater risk of infection and adverse outcomes that immune-suppressed individuals, including many patients with cancer, face from SARS-CoV-2 and to make decisions about staffing for the care of those individuals with thoughtful consideration of that greater risk. Unless no alternative exists, COVID-19 positive health workers, even if asymptomatic, should not be assigned to care for patients with cancer
December 16, 2021
Fifty years ago, just a few days before the new year, former President Richard Nixon signed into law the National Cancer Act (NCA), setting a clear national priority to conquer cancer.
June 22, 2021
Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) assert in a joint position statement released today.
February 17, 2021
In the midst of growing concerns that patients with cancer have limited access to the COVID-19 vaccines, the Association for Clinical Oncology (ASCO) and American Cancer Society Cancer Action Network (ACS CAN), advocacy affiliate of the American Cancer Society, today issued a joint letter to every state governor in the United States urging them to prioritize patients with cancer in the distribution of COVID-19 vaccines in accordance with U.S. Centers for Disease Control and Prevention (CDC) guidelines.
February 9, 2021
The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients. The joint recommendations are detailed in a series of articles published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The series provides a comprehensive examination of eligibility criteria for cancer clinical trials with recommendations to address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
December 23, 2020
The Association for Clinical Oncology (ASCO) applauds the decision by the U.S. District Court for the District of Maryland to grant a temporary restraining order on the implementation of the Most Favored Nation (MFN) Interim Final Rule. Judge Blake’s decision delays the model’s implementation for 14 days while she considers a preliminary injunction, which would further delay the model. The decision notes that there is likely to be irreparable harm if the rule goes into effect January 1, suggesting that the preliminary injunction will likely be granted.
December 17, 2020
The American Society of Clinical Oncology (the Society), an affiliated organization of the Association for Clinical Oncology (the Association), collectively known as ASCO, submitted an amicus curiae brief in support of motions in four cases to enjoin the Most Favored Nation (MFN) Model from taking effect on January 1, 2021. The Society’s friend-of-the-court brief urges the courts to stop implementation of the model, citing its devastating impact on patients.
December 8, 2020
ASCO today issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning from the COVID-19 Experience to Improve Clinical Research and Cancer Care intends to make cancer care and research opportunities more accessible to and equitable for patients in every community. Importantly, ASCO aims, with its recommendations, to address long-standing cancer care disparities that have been highlighted by the pandemic.
August 14, 2020
Greater Coverage, Patient Education, and Research for Telemedicine Needed During Pandemic and Beyond
The American Society of Clinical Oncology released today a position statement that recommends specific actions for applying telemedicine in cancer care during the pandenic and after its expiration.
August 12, 2020
One of the nation’s leading cancer organizations today called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations.
Pages |